Learn about cost, uses, and more of Keytruda ... It’s available only as a brand-name drug. Keytruda isn’t available in a biosimilar form. Biosimilars are like generic drugs.

Keytruda (pembrolizumab) is a brand-name IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects, such as eye ...

Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer. They are given by a healthcare professional as an intravenous (IV) infusion.

Keytruda comes only as a brand-name drug. There are no biosimilar forms available. Biosimilars are like generic drugs. Unlike generics, which are made for nonbiologic drugs, ...

Here are the top 10 best-selling, brand-name drugs of 2024. Opdivo — $9.3 billion Bristol Myers Squibb ( BMY ) and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers ...

A decade later, this brand has entered 53 countries, is reimbursed in 68% of these markets, and has entered a new market at nearly the same rate as Keytruda, 64.5 days on average.

Pembrolizumab, brand name Keytruda, belongs to a class of immunotherapies called checkpoint inhibitors. The drug is an antibody designed to block PD-1, a protein on immune cells that keeps those ...

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new resu… ...

The US Food and Drug Administration (FDA) has approved MSD’s KEYTRUDA regimen as a first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma (MPM ...